Andere talen Vivoryon Therapeutics N.V.

Aandelen

VVY

NL00150002Q7

Beurs gesloten - Euronext Amsterdam Andere beurzen 17:35:03 17-05-2024			Nabeurs 18:53:20
0,798 ^EUR	+6,12%		0,809	+1,38%

24/04	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
24/04	Vivoryon stopt eerder met studie naar middel tegen Alzheimer	AM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024	15/05
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024	08/05
Vivoryon Therapeutics N : to Hold its 2024 Annual General Meetingon June 21, 2024	08/05
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024	08/05
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	24/04
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	24/04
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	24/04
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024	16/04
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Announces Changes to Board Composition	15/03
Vivoryon Therapeutics N.V. Announces Changes to Board Composition	15/03
Vivoryon Therapeutics N.V. Announces Changes to Board Composition	15/03
Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	15/03
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	04/03
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	04/03
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	04/03
Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer?S Disease	04/03
SMALL & MIDCAPS : tour d'Europe des recommandations d'analystes	05/02
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	08/01
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	08/01
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	06/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vivoryon Therapeutics N.V.

Aandelen

VVY

NL00150002Q7

Andere talen

Filters